EGFR and lung carcinoma: By focusing on erlotinib‐resistant colonies that arose from a single, EGFR‐addicted lung cancer cell, another study concluded that drug‐tolerant “persisters” may serve as latent reservoirs for the emergence of resistance mechanisms (Ramirez et al,2016).